Related Experiment Video

Updated: Aug 8, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Clopidogrel resistance: myth or reality?

Aron A Barsky1, Rohit R Arora

  • 1Division of Cardiovascular Disease, Department of Medicine, Chicago Medical School, Chicago, IL 60604, USA.

Journal of Cardiovascular Pharmacology and Therapeutics
|May 17, 2006
PubMed

Insights

Dual antiplatelet therapy is crucial for preventing cardiovascular events. However, some patients exhibit clopidogrel resistance, impacting treatment effectiveness and clinical outcomes, necessitating further research.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelets are key in arterial thrombosis and cardiovascular events.
  • Antiplatelet therapy, particularly dual therapy with aspirin and clopidogrel, is standard for secondary prevention and post-percutaneous coronary intervention.
  • Subacute stent thrombosis persists in 1-2% of patients despite dual antiplatelet therapy.

Purpose of the Study:

  • To review the origins and definition challenges of clopidogrel resistance.
  • To discuss the clinical implications and future challenges of clopidogrel resistance.

Main Methods:

  • Literature review focusing on studies investigating clopidogrel response and resistance.
  • Analysis of existing definitions and proposed mechanisms of clopidogrel resistance.

Main Results:

  • Interindividual variations in response to clopidogrel exist, leading to resistance in a subset of patients.
  • Clopidogrel resistance is linked to adverse clinical outcomes, including stent thrombosis.
  • A universally accepted definition and understanding of clopidogrel resistance mechanisms are currently lacking.

Conclusions:

  • Clopidogrel resistance poses a significant clinical challenge due to its variable definition and unclear mechanisms.
  • Further research is needed to standardize the definition and elucidate the mechanisms of clopidogrel resistance to optimize patient care.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...